Literature DB >> 16924032

CSF BACE1 activity is increased in CJD and Alzheimer disease versus [corrected] other dementias.

R M D Holsinger1, J S Lee, A Boyd, C L Masters, S J Collins.   

Abstract

To assess the diagnostic utility of CSF BACE1 activity for discriminating Alzheimer disease (AD) from other dementias, particularly Creutzfeldt-Jakob disease (CJD), the authors studied 26 patients with sporadic CJD, 21 patients with AD, and 21 patients with various non-AD, non-CJD dementias (DCs). CSF BACE1 activity was elevated in AD in comparison with DC (p = 0.01). Unexpectedly, CSF BACE1 activity was also increased in sporadic CJD (p = 0.02).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16924032     DOI: 10.1212/01.wnl.0000229925.52203.4c

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  28 in total

1.  BACE2 expression increases in human neurodegenerative disease.

Authors:  Christopher J Holler; Robin L Webb; Ashley L Laux; Tina L Beckett; Dana M Niedowicz; Rachel R Ahmed; Yinxing Liu; Christopher R Simmons; Amy L S Dowling; Angela Spinelli; Moshe Khurgel; Steven Estus; Elizabeth Head; Louis B Hersh; M Paul Murphy
Journal:  Am J Pathol       Date:  2011-11-07       Impact factor: 4.307

Review 2.  Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.

Authors:  Harald Hampel; Richard Frank; Karl Broich; Stefan J Teipel; Russell G Katz; John Hardy; Karl Herholz; Arun L W Bokde; Frank Jessen; Yvonne C Hoessler; Wendy R Sanhai; Henrik Zetterberg; Janet Woodcock; Kaj Blennow
Journal:  Nat Rev Drug Discov       Date:  2010-07       Impact factor: 84.694

3.  SORL1 genetic variants and cerebrospinal fluid biomarkers of Alzheimer’s disease.

Authors:  Liang-Hao Guo; Christine Westerteicher; Xin-Hui Wang; Martina Kratzer; Amalia Tsolakidou; Meizi Jiang; Timo Grimmer; Simon M Laws; Panagiotis Alexopoulos; Hideaki Bujo; Alexander Kurz; Robert Perneczky
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-09       Impact factor: 5.270

Review 4.  Biological markers of amyloid beta-related mechanisms in Alzheimer's disease.

Authors:  Harald Hampel; Yong Shen; Dominic M Walsh; Paul Aisen; Les M Shaw; Henrik Zetterberg; John Q Trojanowski; Kaj Blennow
Journal:  Exp Neurol       Date:  2009-10-06       Impact factor: 5.330

5.  Development of a specific ELISA to measure BACE1 levels in human tissues.

Authors:  Amanda Gonzales; Boris Decourt; Aaron Walker; Rachel Condjella; Hikmet Nural; Marwan N Sabbagh
Journal:  J Neurosci Methods       Date:  2011-08-25       Impact factor: 2.390

6.  Protein levels of ADAM10, BACE1, and PSEN1 in platelets and leukocytes of Alzheimer's disease patients.

Authors:  Jessyka Maria de França Bram; Leda Leme Talib; Helena Passarelli Giroud Joaquim; Tamires Alves Sarno; Wagner Farid Gattaz; Orestes Vicente Forlenza
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-05-29       Impact factor: 5.270

Review 7.  Splice variants of the Alzheimer's disease beta-secretase, BACE1.

Authors:  R M Damian Holsinger; Nelleke Goense; John Bohorquez; Padraig Strappe
Journal:  Neurogenetics       Date:  2012-11-11       Impact factor: 2.660

8.  CNS amyloid-β, soluble APP-α and -β kinetics during BACE inhibition.

Authors:  Justyna A Dobrowolska; Maria S Michener; Guoxin Wu; Bruce W Patterson; Robert Chott; Vitaliy Ovod; Yuriy Pyatkivskyy; Kristin R Wildsmith; Tom Kasten; Parker Mathers; Mandy Dancho; Christina Lennox; Brad E Smith; David Gilberto; Debra McLoughlin; Daniel J Holder; Andrew W Stamford; Kevin E Yarasheski; Matthew E Kennedy; Mary J Savage; Randall J Bateman
Journal:  J Neurosci       Date:  2014-06-11       Impact factor: 6.167

9.  Characterization of Cerebrospinal Fluid BACE1 Species.

Authors:  Inmaculada Lopez-Font; Claudia P Boix; Henrik Zetterberg; Kaj Blennow; Javier Sáez-Valero
Journal:  Mol Neurobiol       Date:  2019-07-09       Impact factor: 5.590

Review 10.  Aβ-Degrading Proteases: Therapeutic Potential in Alzheimer Disease.

Authors:  Malcolm A Leissring
Journal:  CNS Drugs       Date:  2016-08       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.